90 -2 (76) 2025 - Khakimova G.G., Khakimov G.A. - THE RESULTS OF COLON CANCER TREATMENT IN TASHKENT

THE RESULTS OF COLON CANCER TREATMENT IN TASHKENT

Khakimova G.G. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Khakimov G.A. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Kadirov Sh.Sh. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Jumaniyozov K.I. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Urmonov U.B. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Resume

The share of CC in Uzbekistan accounts for 6.7%. In the overall structure of oncology incidence, CC ranks 5th, in the structure of mortality - 4th place, almost 25,000 new cases and more than 14,000 deaths from CC are recorded annually. Statistical information is the basis for developing and monitoring the results of anticancer activities. Aim. To study the state of oncology care for patients with CC in the Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology (TCB RSSPMCOR). Materials and methods. According to the retro- and prospective analysis, from 2015 to 2022, 250 patients with colon cancer received treatment at the TCB RSSPMCOR. Of these, stage II 24% (n=61), stage III 47% (n=117), stage IV 29% (n=72). The average age is 59.29.9 years. The lesion of the left intestines prevailed (72.8% versus 37.2%), regardless of the stage. Histologically adenocarcinoma, G2 (97%). Of the 250 patients, 12.4% (n=31) received complex treatment, 55.2% (n=138) combined treatment, 32.4% (n=81) conservative treatment. Surgical treatment was performed in 58% (n=145), colostomy removal in 6.4% (n=16), surgical treatment and colostomy in 10% (n=25). 25.6% (n=64) remained without surgery. Radiation therapy was performed in 12% (n=30) in the pre- or postoperative regime, which amounted to (8% (n=20) vs. 4% (n=10), respectively). Targeted therapy was received by 10% (n=26). Chemotherapy was performed in 99% (n=248) cases. Of these: neoadjuvant - 15.6% (n=39), postoperative - 36.4% (n=91), perioperative - 16% (n=40), palliative - 31.2% (n=78). Results. During the follow-up period (mean 26.4±16.0 months, from 1 to 75 months, median 24.2 months), mortality was 145 (58.0%), progression rate was 220 (88.0%). Increasing the stage worsened overall survival (OS) and progression-free survival (PFS). Two-year OS for stages II, III and IV was 69.7%, 63.2% and 21.9%, p = 0.000001 respectively.2-year PFS for stages II, III and IV was 52.8%, 30.3% and 3%, p = 0, 00001 respectively. Conclusion. There has been a steady increase in morbidity and mortality from CC. Taking into account the neglect of the stage at the initial detection of the tumor, the issues of diagnosing CC in the early stages remain relevant, and the treatment of CC requires compliance with international standards for the treatment of this pathology.

Key words: colon cancer, overall survival, progression-free survival.

First page

482

Last page

489

For citation:Khakimova G.G., Khakimov G.A., Kadirov Sh.Sh., Jumaniyozov K.I., Urmonov U.B. - THE RESULTS OF COLON CANCER TREATMENT IN TASHKENT//New Day in Medicine 2(76)2025 482-489 https://https://newdayworldmedicine.com/en/new_day_medicine/2-76-2025

List of References

  1. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. // CA Cancer J Clin 2021;71:209–49. DOI: 10.3322/caac.21660
  2. Тилляшайхов М.Н., Рахимов О. А., Адилходжаев А. А. и др. Заболеваемость колоректальным раком в Узбекистане. // Тазовая хирургия и онкология 2022;12(2):11-6. DOI: 10.17650/2686-9594-2022- 12-2-11-16.
  3. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040 // Transl Oncol. 2021 Oct;14(10):101174.
  4. Blecher E., Chaney-Graves K., DeSantis C et al. Global cancer facts and figures // American Cancer Society, Atlanta, GA, USA, 2011.
  5. Samee A., Selvaseka R. CR: Current trends in staging rectal cancer. // World J Gastrornterol. 2011;17:828-834.
  6. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A. et al. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. // Int J Mol Sci. 2017;18(197) PubMed/NCBI View Article : Google Scholar
  7. Mohammadian M, Zeynali S, Azarbaijani AF et al. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharm Sci. 2017;12:517-525. PubMed/NCBI View Article : Google Scholar
  8. Recio-Boiles A., Cagir B. Colon cancer. [Updated 2021 Jan. 25]. In: StatPearls. StatPearls Publishing, // Treasure Island, FL, 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/.
  9. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A et al. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. // Int J Mol Sci. 2017;18(197) PubMed/NCBI View Article : Google Scholar
  10. Redondo-Blanco S, Fernández J, Gutiérrez-del-Río I et al. New insights toward colorectal cancer chemotherapy using natural bioactive compounds. // Front Pharmacol. 2017;8(109). PubMed/NCBI View Article : Google Scholar
  11. Li M, Zhang N, Li M. Capecitabine treatment of HCT-15 colon cancer cells induces apoptosis via mitochondrial pathway. // Trop J Pharm Res. 2017;16:1529-1536.
  12. Centelles JJ: General aspects of colorectal cancer. ISRN Oncol. 2012(139268). PubMed/NCBI View Article : Google Scholar
  13. Recio-Boiles A, Kashyap S, Tsoris A and Babiker HM: Rectal Cancer. [Updated 2020 Dec. 17]. In: StatPearls. StatPearls Publishing, Treasure Island, FL, 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493202/.
  14. Государственные ведомственные отчетные формы Министерства здравоохранения Республики Узбекистан. Форма No 7 «Сведения о заболеваниях злокачественными новообразованиями» за 2020 г. [State departmental reporting forms of the Ministry of Health of the Republic of Uzbekistan. Form No. 7 “Information on malignant diseases” for 2020. (In Russ.)].
  15. Состояние онкологической помощи населению Республики Узбекистан в 2019 году. Под ред. М.Н. Тилляшайхова, Ш.Н. Ибрагимова, С.М. Джанклич. Ташкент: ИПТД «Узбекистан», 2020; 176 с. [Situation with cancer care in the Republic of Uzbekistan in 2019. Ed by M.N. Tillyashaykhov, Sh.N. Ibragimov, S.M. Dzhanklich. Tashkent: IPTD “Uzbekistan”, 2020. 176 p. (In Russ.)].
  16. SEER.CANCER.gov

    file

    download